ImmuPharma plc (LON:IMM – Get Free Report) traded up 5.3% during trading on Friday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.69 ($0.05). 100,501,945 shares were traded during trading, an increase of 231% from the average session volume of 30,396,029 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Stock Up 4.9 %
The firm’s 50 day moving average is GBX 1.44 and its 200-day moving average is GBX 1.65. The firm has a market cap of £15.30 million, a PE ratio of -367.30 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
See Also
- Five stocks we like better than ImmuPharma
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
